Zheng, B.; Lou, F.; He, Y.; Fu, M.; Huang, X.; Tan, W.; Chen, Q.; Xie, X.; Hu, T.; Xiao, L.
Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC). Cancers 2025, 17, 657.
https://doi.org/10.3390/cancers17040657
AMA Style
Zheng B, Lou F, He Y, Fu M, Huang X, Tan W, Chen Q, Xie X, Hu T, Xiao L.
Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC). Cancers. 2025; 17(4):657.
https://doi.org/10.3390/cancers17040657
Chicago/Turabian Style
Zheng, Bowen, Fanzhuoran Lou, Yuting He, Miao Fu, Xintian Huang, Weijuan Tan, Quan Chen, Xiaowen Xie, Tianhui Hu, and Li Xiao.
2025. "Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)" Cancers 17, no. 4: 657.
https://doi.org/10.3390/cancers17040657
APA Style
Zheng, B., Lou, F., He, Y., Fu, M., Huang, X., Tan, W., Chen, Q., Xie, X., Hu, T., & Xiao, L.
(2025). Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC). Cancers, 17(4), 657.
https://doi.org/10.3390/cancers17040657
